Stock 1672 ASCLETIS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 01:48:13 2024-04-26 am EDT 		5-day change 1st Jan Change
1.31 HKD -3.68% Intraday chart for Ascletis Pharma Inc. +2.34% -10.27%
Apr. 03 Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus MT
Apr. 03 Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 CI

Business Summary

Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.

Number of employees: 219

Sales per Business

HKD in Million2021Weight2022Weight Delta
Pharmaceutical Products
100.0 %
93 100.0 % 63 100.0 % -32.11%

Sales per region

HKD in Million2021Weight2022Weight Delta
China
100.0 %
86 92.3 % 63 100.0 % -26.48%
Other
0.0 %
7 7.7 % 0 0.0 % -99.58%

Managers

Managers TitleAgeSince
Jinzi Wu CEO
 Chief Executive Officer 61 -
Yan Yuemei CTO
 Chief Tech/Sci/R&D Officer - -
Handan He CTO
 Chief Tech/Sci/R&D Officer - 19-10-06
Zhengqing Li CTO
 Chief Tech/Sci/R&D Officer - 19-02-27
Judy Hejingdao Wu COO
 Chief Operating Officer 50 19-03-12
Joshua Zhongbao PRN
 Corporate Officer/Principal - 18-08-29
Ming Fai Chung SEC
 Corporate Secretary 45 22-08-21
John Gargiulo PRN
 Corporate Officer/Principal - 22-06-11

Members of the board

Members of the board TitleAgeSince
Jinzi Wu CEO
 Chief Executive Officer 61 -
Jiong Gu BRD
 Director/Board Member 51 18-03-31
Judy Hejingdao Wu COO
 Chief Operating Officer 50 19-03-12
Yizhen Wei BRD
 Director/Board Member 49 18-04-26
Lin Hua BRD
 Director/Board Member 50 18-04-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,012,758,000 286,381,323 ( 28.28 %) 0 28.28 %

Shareholders

NameEquities%Valuation
Jinzi Wu
50.79 %
514,393,664 50.79 % 94 M $
Yang Dan
10.41 %
105,463,060 10.41 % 19 M $
Judy Hejingdao Wu
8.178 %
82,827,414 8.178 % 15 M $
CBC Group (Singapore) Pte. Ltd.
6.335 %
64,154,727 6.335 % 12 M $
Ying Yang He
6.190 %
62,689,872 6.190 % 11 M $
JPMorgan Asset Management (China) Co Ltd.
0.4419 %
4,475,000 0.4419 % 817 627 $
Fullgoal Fund Management Co., Ltd.
0.3960 %
4,011,000 0.3960 % 732 850 $
Fullgoal Asset Management (HK) Ltd.
0.0912 %
924,000 0.0912 % 168 824 $
Dimensional Fund Advisors Ltd.
0.0323 %
327,389 0.0323 % 59 817 $
Manulife Investment Management (Hong Kong) Ltd.
0.0168 %
170,000 0.0168 % 31 061 $

Company contact information

Ascletis Pharma, Inc.

HIPARK, 198 Qidi Road Xiaoshan District

311200, Hangzhou

+86 571 8538 9730

http://www.ascletis.com
address Ascletis Pharma Inc.(1672)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Ascletis Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.259 CNY
Average target price
2.752 CNY
Spread / Average Target
+118.65%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ASCLETIS PHARMA INC. Stock Ascletis Pharma Inc.
-10.27% 176M
CSL LIMITED Stock CSL Limited
-4.70% 87.53B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.63% 40.42B
BIOGEN INC. Stock Biogen Inc.
-21.76% 29.48B
UCB Stock UCB
+58.56% 25.43B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.78% 15.59B
INCYTE CORPORATION Stock Incyte Corporation
-18.49% 11.49B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-15.61% 11.1B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.02% 11.3B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.17% 8.75B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1672 Stock
  4. Company Ascletis Pharma Inc.